ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0756

Validation of Two Simple Patient-centered Outcome Measures for Virtual Monitoring of Patients with Idiopathic Inflammatory Myositis

R Naveen1, Darpan R Thakare2, Vikas Agarwal2, Rohit Aggarwal3 and Latika Gupta1, 1Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, 2Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 3University of Pittsburgh, Pittsburgh, PA

Meeting: ACR Convergence 2021

Keywords: dermatomyositis, Myositis, Outcome measures, Patient reported outcomes

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Changing landscape of patient care from in-person to virtual telemedicine-based consultation in times of a global pandemic has necessitated a wider use of patient-centered outcomes measures (PCOMs) and device-based measures for objective disease assessment. We prospectively validated 2 novel task based PCOMs for physical function, namely Arm Lift test (AL) & Two-Minute Walk Distance (2MWD) in idiopathic myositis (IIM) patients.

Methods: This was a prospective observational study with enrolment of adult patients with IIM in the MyoCite cohort (2017 ACR/EULAR criteria). Both active and inactive disease patients were enrolled. Active disease was defined as escalation of immunosuppression within 3 months, elevated muscle enzymes, physician VAS >2, skin disease worsening or fall in MMT8< 76 (any 2).

Two novel tests were performed at baseline; AL: Time taken for arm abduction ten times & 2MWD: distance walked in 2 minutes. We also evaluated all myositis core set measures [MMT 8, patient and physician global disease activity (PtGA and PhGA), HAQ-DI, extra-muscular disease activity as well as MDAAT & MDI]. Test-discriminant validity was tested between active and inactive myositis.

The results were validated in a larger Teleconsultation-based cohort to differentiate active vs. inactive disease. All values are in median(IQR).

Results: Observation cohort

22 adult IIM patients (68% female) of age 30.5 (19-62) years were enrolled. Median AL time, 2MWD and MMT-8 were 11.9 (10.5-14) seconds, 198 (167-225) metres and 79 (74-80) respectively.

AL and 2MWD showed excellent test-retest reliability (Cronbach’s alpha 0.987 & 0.99 respectively, n=12). AL test had moderate to strong correlation all myositis core set measures including MMT8, PtGA, PhGA, HAQ-DI, Extra-muscular global (Ex-MuscGA), muscle enzyme (LDH, AST, ALT) and MYOACT (trend), but not with CK levels and MDI (table 1). In addition it showed moderately strong association with muscle disease VAS and muscle disease remission. In contrast, 2MWD had huge variability and no significant association with any of the core set or other measures except a moderate correlation with muscle VAS.

A higher AL time discriminated active and inactive myositis (16.6 vs 11 seconds, p=0.006) and discriminated between patients with and without muscle weakness (significant) and HAQ (non-significant trend) (Figure 1 A-C). However, 2MWD didn’t discriminate based on muscle disease activity or other measures.

AUC for active versus inactive disease was 0.882 (p 0.006) with AL test. A cut-off of 12.8 seconds had 94% negative predictive values for active muscle disease (83% sensitivity, 83% specificity).

Validation cohort

In 47 patient visits among 26 patients (81% female, 33 years median age), AL significantly differentiated between active vs. inactive patients (Figure 2).

Conclusion: AL correlated well with myositis disease activity measures including muscle weakness providing preliminary evidence for its role as PCOM in IIM especially in clinical trials and telemedicine consultation. 2MWD was not a good test for outcome evaluation of IIM patients. Larger longitudinal studies are needed to further validate these findings.

Figure 1. Arm lift test variation based on muscle disease remission (A), MMT8 (B) and HAQ-DI (C).

Figure 2. Arm Lift test in active versus inactive disease in Validation cohort (47 patient visits)

Table 1. Correlation of Arm lift test and 2MWD with disease parameters (Construct Validity) in observation cohort (n=22)


Disclosures: R. Naveen, None; D. R Thakare, None; V. Agarwal, None; R. Aggarwal, Mallinckrodt, 1, 5, Bristol Myers-Squibb, 2, 5, Pfizer, 2, Genentech, 5, Orphazyme, 1, 2, CSL Behring, 1, 2, AstraZeneca, 2, Kezar, 2, Q32, 2, 5, Alexion, 2, Argenx, 2, Boehringer Ingelheim, 2, Corbus, 2, EMD Serono, 2, 5, Janssen, 2, Kyverna, 2, Octapharma, 1, 2; L. Gupta, None.

To cite this abstract in AMA style:

Naveen R, R Thakare D, Agarwal V, Aggarwal R, Gupta L. Validation of Two Simple Patient-centered Outcome Measures for Virtual Monitoring of Patients with Idiopathic Inflammatory Myositis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/validation-of-two-simple-patient-centered-outcome-measures-for-virtual-monitoring-of-patients-with-idiopathic-inflammatory-myositis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validation-of-two-simple-patient-centered-outcome-measures-for-virtual-monitoring-of-patients-with-idiopathic-inflammatory-myositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology